Sign inJoin
Company / Finance

ABVC BioPharma, Inc.

ABVC · NASDAQ

ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.

FollowAdd to WatchlistAsk Question
NASDAQABVCCoverage BootstrapBiotechnologyBotanical DrugsOphthalmology
Latest ReportMay 13, 2026ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balanceView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
ABVC
Clear tags
Latest Thesis

ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balance

ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
ABVC BioPharma, Inc.BioPharma: zero revenue, $21M of assets, and a pipeline too wideMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balanceABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.NASDAQMay 13, 2026Research reportReadSlides